



New Data Highlight Aranesp Efficacy in Anemic Patients with Lymphoid Cancer

June 16, 2003

FOR IMMEDIATE RELEASE

LYON, FRANCE, June 16, 2003 - Amgen (Nasdaq:AMGN), the world's largest biotechnology company, presented data showing that three times as many anemic patients with lymphoid cancers receiving Aranesp® (darbepoetin alfa) experienced increases in hemoglobin levels compared to those receiving placebo. These data support the recent recommendation by the European Committee on Proprietary Medicinal Products (CPMP) to extend the Aranesp® label to include treatment of chemotherapy-induced anemia in adult patients with non-myeloid malignancies. Results from the study were presented at the European Hematology Association meeting by Michael Hedenus, MD, of Sundsvall Hospital, Sundsvall, Sweden.

"Our study addressed the question of whether myelomas responded better than lymphomas to treatment with erythropoietic proteins. We found that Aranesp® was equally efficacious in patients with myeloma and lymphoma," said Dr. Hedenus. "Given the prevalence of anemia among chemotherapy patients, these data provide important insight into how doctors can best manage this serious and debilitating condition."

In the multi-center double-blind trial, 349 adults with lymphoid system cancers and hemoglobin levels ≤ 11.0 g/dL were randomized to receive Aranesp® or placebo for

12 weeks. Dr. Hedenus reported that, overall, 60 percent of patients receiving Aranesp® achieved an increase in hemoglobin of ≥ 2.0 g/dL from baseline, compared to only 18 percent in the placebo group, (p